louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01055041: Controller Medications in the Management of Bronchial Asthma
Official title: A Randomized, Open Labeled Comparative Study to Assess the Efficacy and Safety of Controller Medications as Add on to Inhaled Steroid and Long Acting β2 Agonist in Treatment of Moderate to Severe Persistent Bronchial Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Moderate to Severe Persistent Bronchial Asthma
Lead sponsor: Government Medical College, Bhavnagar
Sponsor class: OTHER
First posted: 2010-01-25
Enrollment: 50
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe persistent bronchial asthma.


Eligibility criteria: Inclusion Criteria:

* aged between 15 to 65 years of either sex
* had clinically diagnosed Bronchial asthma
* had poor asthma control defined by ACQ score (asthma control questionnaire) of 1.5 or greater
* FEV1 (Forced Expiratory Volume at 1 second) value of 50% or more of predicted
* improvement in FEV1 was greater than 15% after bronchodilator inhalation

Exclusion Criteria:

* major illness of system other than respiratory major respiratory illness other than asthma taken long acting anti histaminic within a preceding week of enrollment Smokers Pregnant and lactating woman history of hypersensitivity to any of above drugs

Primary outcomes:
measure: The primary outcome was percentage of improvement in FEV1
timeFrame: 10 weeks
Secondary outcomes:
measure: Improvement in PEFR (Peak expiratory flow rate), ACQ scores(asthma control questionnaire score), rates of adverse drug reaction and EPACs (episodes of poor asthma control)
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Bhavnagar
country: India
facility: Sir Takthasinhji General Hospital Bhavnagar, Gujarat, India
state: Gujarat
Study officials:
affiliation: Sir T. General Hospital and Government Medical College, Bhavnagar-364001, Gujarat, India
name: Dr. Yogesh A Patel, M.B.B.S
role: PRINCIPAL_INVESTIGATOR
affiliation: Professor and Head, Department of Pharmacology, Government Medical College, Bhavnagar-364001, Gujarat, India
name: Dr. Chandrabhanu R Tripathi, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00004341: Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: X-Linked Agammaglobulinemia
X-Linked Hyper IgM Syndrome
Wiskott-Aldrich Syndrome
Leukocyte Adhesion Deficiency Syndrome
Keywords: Wiskott-Aldrich syndrome
X-linked agammaglobulinemia
X-linked hyper IgM syndrome
genetic diseases and dysmorphic syndromes
immunologic disorders and infectious disorders
leukocyte adhesion deficiency syndrome
primary immunodeficiency disease
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: University of Washington
First posted: 1999-10-19
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders.

II. Explore the mutations within each syndrome to better understand the genetics of these disorders.

III. Study the function of the Wiskott-Aldrich syndrome proteins (WASP). IV. Design methods to identify carriers and for prenatal diagnosis. V. Explore new avenues for therapy.

Detailed description: PROTOCOL OUTLINE: Patients are studied systematically to determine the extent of their immune deficiency and to confirm a specific diagnosis. Patients with a known immunodeficiency syndrome are studied in detail to identify the gene mutation, to assess the effect of the mutation on the gene product, and to establish cell lines for further in vitro assessment of the genetic defect. The function of Wiskott-Aldrich syndrome proteins (WASP) in hematopoietic cells is studied.

Family members of patients with X-linked disorders are studied to identify carrier females.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

Primary immunodeficiency disease, e.g.: Leukocyte adhesion deficiency syndrome Wiskott-Aldrich syndrome X-linked agammaglobulinemia X-linked hyper IgM syndrome

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington School of Medicine
state: Washington
Study officials:
affiliation: University of Washington
name: Hans D. Ochs
role: STUDY_CHAIR
References:
citation: Miki H, Nonoyama S, Zhu Q, Aruffo A, Ochs HD, Takenawa T. Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation. Cell Growth Differ. 1997 Feb;8(2):195-202.
citation: Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997 Oct 1;90(7):2680-9.
Clinical trial NCT00772941: Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Official title: Drug Use Investigation Of Champix (Regulatory Post Marketing Commitment Plan)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking Cessation
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-10-15
Enrollment: 3939
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The patients whom an investigator involving A3051109 prescribes the Varenicline(Champix).

Brief summary: The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Detailed description: All the patients whom an investigator prescribes the first Varenicline(Champix) should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria: Inclusion Criteria:

* Patients need to be administered Varenicline(Champix) in order to be enrolled in the surveillance.

Exclusion Criteria:

* Patients not administered Varenicline(Champix).

Primary outcomes:
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender.
timeFrame: 24 weeks
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Age.
timeFrame: 24 weeks
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication.
timeFrame: 24 weeks
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Drugs.
timeFrame: 24 weeks
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies.
timeFrame: 24 weeks
measure: Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline.
timeFrame: 24 weeks
measure: Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day.
timeFrame: 24 weeks
measure: Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks.
timeFrame: 24 weeks
measure: Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.
timeFrame: 24 weeks
measure: Number of Participants With Treatment Related Adverse Events.
timeFrame: 24 weeks
measure: Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.
timeFrame: 24 weeks
Secondary outcomes:
measure: Number of Participants With Continuous Abstinence Situation by 52 Weeks.
timeFrame: 52 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01792141: Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment
Official title: The Use of Fluorescein-Indocyanine Green Angiography in Patients With Diabetic Macular Edema to Identify Areas of Increased Leakage and Provide Targeted Focal Laser Treatment.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Macular Edema
Lead sponsor: Retina Institute of Hawaii
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Clinically Significant Macular Edema

Brief summary: The use of Indocyanine green diagnostic dye will identify areas of vascular leakage which will provide more effective laser treatment by targeting these specific areas.

Detailed description: The Early Treatment of Diabetic Retinopathy Study showed that early treatment of Clinically Significant Macular Edema (CSME) with focal and grid laser preserved vision in diabetic patients. Indocyanine Green angiography, which was not available at the time of the Early Treatment Diabetic Retinopathy Study (ETDRS), is now standard-of-care for diagnostic evaluation of the choroidal circulation and is routinely done in combination with Fluorescein angiography for a more complete visualization of retinal pathology. Simultaneous examination of both retinal and choroidal circulation allows for identification of microaneurysms that are hyperfluorescent both on Fluorescein angiography and Indocyanine green angiography. Such microaneurysms are sites of increased vascular leakage and represent a means for providing more effective laser treatment by targeting these areas directly with focal laser.

Eligibility criteria: Inclusion Criteria:

* Meets criteria for Clinically Significant Macular Edema
* Microaneurysms hyperfluorescent

Exclusion Criteria:

* Increase intraocular pressure
* Intraocular inflammation
* Retinal detachment

Primary outcomes:
measure: Primary objective is to assess the effectiveness of FA-ICG guided focal laser therapy for the treatment CSME by means of serial FA-1CGs before and every 3 months after treatment.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Retina Institute of Hawaii
state: Hawaii
Study officials:
affiliation: Retina Institute of Hawaii
name: Michael D Bennett, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01645241: Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
Official title: Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: INFERTILITY
Fertility Preservation
Ovulation Induction
Vitrification
Oocyte Donation
Keywords: Ovarian stimulation
Luteal phase
Egg donors
Fertility preservation
Lead sponsor: Fundacion Dexeus
Sponsor class: OTHER
Collaborators: name: FUNDACION DEXEUS SALUT DE LA DONA
name: Ayudas Merck Serono de Investigación 2012
First posted: 2012-07-20
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients


Eligibility criteria: Inclusion Criteria:

* premenopausal women, 18-35 years old, FSH levels \< 10 mIU/ml; AFC\> 10
* regular cycles
* BMI \< 28
* signed informed consent

Recipients:

* Infertile women eligible for oocytes donation
* BMI \< 35
* Signed informed consent form

Exclusion Criteria:

-Polycystic ovarian syndrome, gonadotropins allergy

Recipients:

* Women eligible for oocytes donation
* BMI \>35
* Uncontrolled Endocrine Pathology

Primary outcomes:
measure: Pregnancy rate
timeFrame: six weeks after transfer procedure
Secondary outcomes:
measure: Number of Mature oocytes
timeFrame: Day of oocyte retrieval
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus
Study officials:
affiliation: Fundación Dexeus Salut de la Dona
name: Francisca Martínez, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011 May;95(6):2125.e9-11. doi: 10.1016/j.fertnstert.2011.01.030. Epub 2011 Feb 3.
citation: von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009 Oct;92(4):1360-1365. doi: 10.1016/j.fertnstert.2008.08.011. Epub 2008 Oct 18.
citation: Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, Sole M, Tur R, Coroleu B, Barri PN. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril. 2014 Nov;102(5):1307-11. doi: 10.1016/j.fertnstert.2014.07.741. Epub 2014 Aug 22.
Clinical trial NCT02942641: Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Short-term Management of Hospitalized Patients With Transient Acute Urinary Retention
Official title: Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Short-term Management of Hospitalized Patients With Transient Acute Urinary Retention: A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Urinary Retention
Keywords: Urethral catheter
clean intermittent catheterization
UTI
pain
quality of life
hematuria
cloudy urine
Lead sponsor: Ramathibodi Hospital
Sponsor class: OTHER
First posted: 2016-10-24
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: Acute urinary retention (AUR) is a common problem in hospitalized patients. Either indwelling urethral catheterization or clean intermittent catheterization (CIC) can be the choice of treatment. In chronic urinary retention, most physicians prefer CIC to chronic indwelling urethral catheter on the basis of the claim that the rate of catheter-associated urinary tract infection (CAUTI) is lower.

Method: The patients were randomized into indwelling urethral catheter and CIC groups. The primary outcomes of the study were catheter-associated asymptomatic bacteriuria and CAUTI. The secondary outcomes were pain, hematuria, cloudy urine, and quality of life.

Detailed description: We queried the hospitalized patients in Ramathibodi Hospital who developed first-time AUR from June 2014 to May 2015. Patients under 18 years of age with a history of urinary retention, urinary tract infection, and poor compliance were excluded from this study. All the patients gave their written informed consents. The patients were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.

All the patients were followed up after 2 weeks; urinalysis and urine culture were obtained at the time of AUR and whenever the patients developed UTI-associated symptoms. The patients with positive urine culture at the time of AUR were excluded from the study.

Eligibility criteria: Inclusion Criteria:

* Hospitalized patients in Ramathibodi Hospital who developed first-time AUR from June 2014 to May 2015.

Exclusion Criteria:

* Patients under 18 years of age
* History of urinary retention
* Urinary tract infection
* Poor compliance

Primary outcomes:
measure: Catheter-associated urinary tract infection (CAUTI)
timeFrame: up to 12 months
Secondary outcomes:
measure: Pain
timeFrame: up to 12 months
measure: Hematuria
timeFrame: up to 12 months
measure: Cloudy urine
timeFrame: up to 12 months
measure: Quality of life
timeFrame: up to 12 months
measure: Catheter-associated asymptomatic bacteriuria
timeFrame: up to 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04780841: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Official title: A Two-Part Proof-of-Concept Study: An Open-Label Dose-Ranging Phase (Part A) Followed by a Randomized, Single-Blind, Placebo-Controlled Phase (Part B) Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hyperkalemia
Lead sponsor: Ardelyx
Sponsor class: INDUSTRY
First posted: 2021-03-04
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: In Part A, treatment arms will be dosed based on the results from the previous arm. For Part B, one treatment arm from Part A will be selected
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels


Eligibility criteria: Inclusion Criteria:

1. Males or females aged 18 to 85 years, inclusive
2. Serum potassium value 5.1 to \<6.5 mmol/L
3. Chronic kidney disease with eGFR ≥20 to \<60 mL/min/1.73m2
4. Able to understand and comply with the protocol
5. Willing and able to sign informed consent

Exclusion Criteria:

1. Pseudo-hyperkalemia signs and symptoms
2. Treatment with potassium-lowering drugs within 7 days prior to enrollment/randomization
3. Treatment with glucocorticoids
4. Uncontrolled Type 2 diabetes, defined as most recent historical HbA1c \> 10%, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months
5. Diabetic ketoacidosis
6. Severe heart failure, defined as NYHA (New York Heart Association) Class IV or hospitalization to treat heart failure in previous 3 months
7. History of bowel obstruction, severe gastrointestinal disorders, or major gastrointestinal surgery (e.g., large bowel resection)
8. Females who are pregnant, lactating, or not willing to use appropriate contraception

Primary outcomes:
measure: Change in serum potassium; Part A
timeFrame: 1 week
measure: Change in serum potassium; Part B
timeFrame: 4 weeks
Secondary outcomes:
measure: Exporatory Objective; time to serum potassium normalization
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: Horizon Research Group LLC
state: Florida
city: Miami Lakes
country: United States
facility: Panax Clinical Research LLC
state: Florida
city: Miami Springs
country: United States
facility: South Florida Research Phase I-IV; Inc.
state: Florida
city: Shreveport
country: United States
facility: NW Louisiana Nephrology Assoc
state: Louisiana
city: Kansas City
country: United States
facility: Clinical Research Consultants
state: Missouri
city: Asheville
country: United States
facility: Mountain Kidney & Hypertension Associates
state: North Carolina
Study officials:
References:
Clinical trial NCT05534841: Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Official title: Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rectal Neoplasms
Keywords: MRI
Complete response
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2022-09-10
Enrollment: 99
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Digestive surgery department

Brief summary: Standard care for locally advanced rectal cancer consists in a neoadjuvant therapy followed by surgery. Morbidity and mortality remain high after rectal surgery, and often linked with quality of life impairment. 10 to 30% present a pathological complete response after neoadjuvant therapy. Some surgical teams propose "watch and wait" approach for patients selected with clinical complete responses criterion. The problem is to be sur the response is complete. MRI seems to be accurate to select complete responders. We will try to find MRI criterion of complete responses.


Eligibility criteria: Inclusion Criteria:

* Rectal adenocarcinoma
* Locally advanced
* Neoadjuvant therapy
* MRI restaging
* Rectal surgery
* Definitive anatomopathology study

Primary outcomes:
measure: Complete response MRI criterion
timeFrame: Day 0: immediately after the procedure
Secondary outcomes:
measure: MRI accuracy
timeFrame: Day 0: immediately after the procedure
Other outcomes:
Locations:
city: Nîmes
country: France
facility: Chu de Nîmes
state: Gard
Study officials:
References:
Clinical trial NCT03536741: Role of TAP and RS Block in Reduction of Postoperative Pain for Gynecological Surgical Laparoscopic Procedures
Official title: The Role of Transversus Abdominis Plane Block and Rectus Sheath Block in Reduction of Postoperative Pain for Gynecological Benign Surgical Laparoscopic Procedures: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: TAP and RS Block
Lead sponsor: Campus Bio-Medico University
Sponsor class: OTHER
First posted: 2018-05-25
Enrollment: 70
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The present study aims to demonstrate the effectiveness of loco-regional wall anesthesia of the transversus abdominis plane block (TAP block) and the rectus sheath block (RS block), compared to intravenous analgesia, in terms of pain reduction, postoperative analgesic drugs consumption, patient satisfaction and decrease of LOS (length of stay), in patients undergoing benign gynecological laparoscopic surgical procedures.


Eligibility criteria: Inclusion Criteria:

* patients undergoing benign laparoscopic gynecological surgery
* age between 18 and 75 years
* BMI \>18 e \<35
* ECOG Performance Status 0-1

Exclusion Criteria:

* age \< 18 or \> 75 years
* BMI \<18 or \> 35
* ECOG Performance Status \>1
* Allergy to local anesthetics
* Allergy to NSAIDs
* Chronic kidney failure \> II class
* Systemic neoplastic disease actual or previous
* Actual pregnancy
* Active or recent pelvic inflammation
* Persistent coagulopathy
* Previous opioids consumption for chronic pain
* Neurological or cognitive disorders
* Conversion from laparoscopic to open surgery
* Onset of intraoperative complications

Primary outcomes:
measure: postoperative pain in the first 72 hours after gynecological surgical procedures
timeFrame: postoperative pain in the first 72 hours after gynecological surgical procedures
measure: analgesic consumption in the first 72 hours after gynecological surgical procedures
timeFrame: analgesic consumption in the first 72 hours after gynecological surgical procedures
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Campus Bio-medico
state: RM
Study officials:
References: